A blinded randomised placebo-controlled trial investigating the efficacy of morphine analgesia for procedural pain in infants: Trial protocol [version 1; peer review: 2 approved, 1 approved with reservations] by Slater, R et al.
 Open Peer Review
Any reports and responses or comments on the
article can be found at the end of the article.
STUDY PROTOCOL
A blinded randomised placebo-controlled trial investigating the
efficacy of morphine analgesia for procedural pain in infants:
 Trial protocol [version 1; peer review: 2 approved, 1 approved
with reservations]
Rebeccah Slater ,         Caroline Hartley , Fiona Moultrie , Eleri Adams , Ed Juszczak ,
       Richard Rogers , Jane E. Norman , Chetan Patel , Kayleigh Stanbury ,
   Amy Hoskin , Gabrielle Green , Poppi Trial Team
Department of Paediatrics, University of Oxford, Oxford, UK
National Perinatal Epidemiology Unit (NPEU), University of Oxford, Oxford, UK
Nuffield Department of Anaesthetics, John Radcliffe Hospital, Oxford, UK
MRC Centre for Reproductive Health, The Queen’s Medical Research Institute, Edinburgh, UK
Oxford Eye Hospital, John Radcliffe Hospital, Oxford, UK
Abstract
Infant pain has both immediate and long-term negative consequences, yet
in clinical practice it is often undertreated. To date, few pain-relieving drugs
have been tested in infants. Morphine is a potent analgesic that provides
effective pain relief in adults, but there is inconclusive evidence for its
effectiveness in infants. The purpose of this study is to establish whether
oral morphine provides effective analgesia for procedural pain in infants.
 
A blinded, placebo-controlled, parallel-group randomized, phase II, clinical
trial will be undertaken to determine whether morphine sulphate
administered orally prior to clinically-required retinopathy of prematurity
(ROP) screening and heel lancing provides effective analgesia. 156 infants
between 34 and 42 weeks’ gestational age who require a clinical heel lance
and ROP screening on the same test occasion will be included in the trial.
Infants will be randomised to receive either a single dose of morphine
sulphate (100 μg/kg) or placebo. Each infant will be monitored for 48 hours
and safety data will be collected during the 24 hours following drug
administration.
 
The primary outcome will be the Premature Infant Pain Profile–revised
(PIPP-R) score 30 seconds after ROP screening. The co-primary outcome
will be the magnitude of nociceptive-specific brain activity evoked by a
clinically-required heel lance. Infant clinical stability will be assessed by
comparing the number of episodes of bradycardia, tachycardia,
desaturation and apnoea, and changes in respiratory support requirements
in the 24-hour periods before and after the clinical intervention. In addition,
drug safety will be assessed by considering the occurrence of apnoeic and
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 drug safety will be assessed by considering the occurrence of apnoeic and
hypotensive episodes requiring intervention in the 24-hour period following
drug administration. This study has been published as an Accepted
by  .Protocol Summary The Lancet
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Background and rationale
Context
The Protocol for our clinical trial titled ‘A blinded randomised 
placebo-controlled trial investigating the efficacy of morphine 
analgesia for procedural pain in infants’ is presented here.
A brief summary of the Trial Protocol has already been pub-
lished by The Lancet as an Accepted Protocol Summary1. The full 
Protocol was reviewed by The Lancet Editorial Board and three 
external reviewers, with a view to publishing the results once 
data collection is complete2,3. Following The Lancet review proc-
ess key changes were made to the Protocol (Amendment 1) and 
prior to the recruitment further amendments were made following 
review by the Medicines and Healthcare products Regulatory 
Authority (MHRA) (Amendment 2) and following a change in the 
drug manufacturer (Amendment 3 & 4).
Background
Pain in infancy is a serious clinical issue. While infant pain is 
recognised to have both immediate and long-term consequences, 
it is still drastically under-treated in this population. Although an 
infant receiving intensive care will experience an average of 10 
painful procedures per day, specific analgesia is provided less than 
25% of the time4. Furthermore, this provision of analgesia includes 
‘comfort techniques’ (such as skin-to-skin maternal contact) and 
does not specifically refer to pharmacological analgesia, which 
would be routinely used in older children and adults4.
Despite the high burden of pain in the neonatal population, less 
than 40% of UK neonatal units have a Pain Management Protocol5. 
The historical misconception that infants do not ‘feel’ pain 
has led to the predisposition to under-treat pain in clinical 
practice6. For example, surveys of neonatal practice demonstrate 
that 50% of neonatal units in the UK and US do not routinely pro-
vide premedication for highly invasive elective intubation, despite 
evidence of clinical benefit7,8. If infants are to receive the best 
possible care a change in clinical practice is needed whereby there 
is an expectation to recognise and effectively treat infant pain. As 
such, it is essential that clinical trials that test the efficacy of analge-
sic medication be conducted using specific and sensitive measures 
of infant pain.
Retinopathy of prematurity (ROP) screening
The most vulnerable infants, with the highest burden of pain, are 
those born prematurely who require intensive neonatal care. In 
the UK, newborn infants admitted to neonatal intensive care units 
(NICU) will be hospitalised for an average of 56 days, and the 
youngest and sickest infants will experience up to 50 painful proce-
dures per day4,9. Retinopathy of Prematurity (ROP) screening is an 
example of a highly invasive medical procedure that is repeatedly 
performed on premature infants. ROP is a condition of the retinal 
vascular system that affects premature infants, which if untreated, 
can lead to permanent blindness. As such there is a national ROP 
screening programme, which involves regular ophthalmic screen-
ing of premature infants to identify whether ROP treatment is 
necessary. Unfortunately, ROP screening is considered to be 
painful10, and is stressful for both infants and parents11. Infants 
are extremely unsettled both during and after the procedure, 
and increased pain scores12, increased salivary cortisol13, and an 
increased likelihood of apnoeic episodes in the 24 hour period 
after screening have been reported14.
Pain management strategies that have been used for ROP screen-
ing include the use of topical local anaesthetic, sucrose and breast 
milk, but they have all been shown to be inadequate for reducing 
pain15–17. Indeed, a recent Cochrane review examining the use of 
local anaesthetic concluded that “screening remains a painful 
procedure and the role of non-pharmacological and pharmaco-
logical intervention including different local anaesthetic agents 
should be ascertained in future randomised trials”15. The level 
of clinical distress caused by this procedure is exemplified in a 
recent study, which reports that in the 24-hour period following 
ROP screening 41% of infants have apnoeic episodes compared to 
only 19% after the examination14.
It is plausible that the immediate distress caused to an infant 
during ROP screening and the resultant physiological instability 
that follows the examination may be alleviated if effective pain 
relief is provided during the procedure.
Morphine analgesia
Morphine is a potent analgesic that provides effective pain relief 
for procedural pain in adults18 but evidence for its effectiveness in 
infants is less clear. Morphine is commonly used on neonatal units as 
a sedative. For example, during mechanical ventilation intravenous 
morphine has been shown to reduce physiological instability; reduce 
behavioural and hormonal stress responses; and improve ventilator 
synchrony19. Although morphine clearly provides effective seda-
tion in infants, the efficacy of morphine as an analgesic remains 
controversial20–22. A recent Cochrane review concluded that there is 
insufficient evidence to recommend routine clinical use of morphine 
for procedural pain relief in mechanically ventilated infants23. To 
date, no randomised controlled trials have been completed whereby 
morphine has been administered to healthy non-ventilated infants 
prior to acute painful procedures. Given the need for analgesics 
in the neonatal population and the limited availability of other 
analgesic drugs, it is essential that the efficacy of morphine anal-
gesia be properly tested. It is plausible that administration of mor-
phine prior to ROP screening may provide effective pain relief and 
consequently reduce the resultant physiological instability caused 
by the procedure.
To date only one trial has attempted to test whether morphine anal-
gesia can reduce pain during ROP screening24. While the results 
of this study suggested that morphine may provide effective pain 
relief, unfortunately, the trial was stopped prematurely due to 
changes to research regulations of the Medicines and Healthcare 
products Regulatory Authority (MHRA) and the need to obtain 
new approval to continue the study. The authors determined a 
sample size of 63 infants was needed, but were only able to recruit 
18 infants in the study period and so did not reach the sample 
size necessary to detect whether morphine caused a significant 
reduction in pain scores24.
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Clinical measures of pain in infants
Measures of pain in infants primarily rely on measuring changes 
in infant behaviour in response to noxious events. In premature 
infants the most validated clinical pain tool is the Premature Infant 
Pain Profile (PIPP)25,26. The PIPP primarily relies on the quantifi-
cation of behavioural and physiological responses that are evoked 
by noxious stimulation. As PIPP is a composite multimodal meas-
ure, incorporating measures of heart rate, oxygen saturation and 
facial expression change, it allows for different aspects of the infant 
pain experience to be captured. It is well-validated for pain assess-
ment in premature infants and has been widely used as the primary 
outcome measure for infant pain in many clinical trials27–29. If 
administration of morphine prior to ROP screening significantly 
reduced subsequent pain scores, there would be a strong rationale 
for its use in clinical practice.
Measures of nociceptive-specific brain activity and reflex 
withdrawal activity
While behavioural measures are presently the gold standard for the 
assessment of pain, new electrophysiological techniques have more 
recently been developed to identify patterns of nociceptive brain 
and spinal cord activity in infants30,31. These objective and quantifi-
able neurophysiological measures have been used as the primary 
outcome measure in a recent clinical trial published in The Lancet, 
providing evidence to suggest that sucrose may not provide analge-
sia during clinical heel lancing32. It would be highly advantageous 
to use these electrophysiological measures of nociceptive brain and 
spinal cord activity in clinical trials investigating the efficacy of 
morphine analgesia. This will provide a unique opportunity to gain 
a mechanistic insight into how morphine alters nociceptive activity 
in the immature infant central nervous system.
Measures of nociceptive brain activity evoked by ROP screen-
ing cannot be easily recorded due to difficulties in identifying the 
precise time when the nociceptive stimulus is applied. However, 
nociceptive-specific patterns of brain activity have been extremely 
well-characterised following clinical heel lancing30,31,33. Heel lanc-
ing is a clinical procedure frequently performed in neonates to 
provide blood samples for the monitoring of jaundice, blood 
sugar, electrolytes and other haematological parameters. Due to 
the frequency of this procedure (which can be performed multiple 
times a day in some premature infants) it is feasible to arrange that 
ROP screening occurs immediately after a clinical blood sample 
is taken. The opportunity to perform ROP screening and a clinical 
heel lance on the same occasion means it is possible to administer 
morphine or a placebo in advance of both procedures. Therefore it 
is feasible to not only test whether morphine effectively reduces 
clinical pain scores during ROP screening but also to establish 
whether morphine reduces nociceptive brain and spinal cord 
activity evoked by a noxious heel lance.
Benefits and risks
The benefit of this trial is that we will determine whether pre- 
emptive administration of morphine provides effective pain relief 
for acute procedural pain in infants. Not only would effective pain 
relief make the infants more comfortable during these procedures 
but it may also improve the physiological stability of the infants in 
the 24-hour period after the procedure. Furthermore, the provision 
of effective pain relief may reduce not prevent the long-term struc-
tural white matter damage and deficits in cognitive ability that have 
been directly linked to the number of painful experiences that 
hospitalised infants receive during their neonatal care34.
There are risks associated with the administration of morphine, 
which include increased hypotension and respiratory depression35. 
However, in studies in ventilated infants where approximately 
double the dose of morphine proposed in this trial was used, there 
was no difference in blood pressure during the first hour after infu-
sion, the fraction of inspired oxygen during the 12 hours after 
infusion, or the number of infants with hypotension requiring 
treatment, between the morphine-treated and control not control-
treated infants36. The authors do, however, report a trend towards 
increased hypotension and ventilator requirements, which they 
considered is likely to be driven by the administration of the 
morphine. In a separate retrospective study, where safety of 
morphine administration in non-intubated infants was investi-
gated, significant differences in hypotension were not observed, 
although there was a suggestion that increased ventilator support 
was required when 2 infants were included who had been acci-
dentally overdosed – the difference between the groups was not 
significant when the overdosed infants were excluded35. While 
there are side effects associated with the administration of 
morphine – which will be further investigated as part of this study 
– the benefit of providing adequate pain relief is likely to out-
weigh the possible adverse consequences. Given that morphine is 
commonly administered to hospitalised infants the importance of 
investigating the efficacy and safety of morphine for procedural 
pain is clear.
Justification for trial
ROP screening is a clinically-essential procedure which is known to 
cause pain and distress in infants, and often results in an extended 
period of clinical instability10,12. Numerous pain management 
strategies have been shown to be ineffective for ROP screening, 
including the use of sucrose, breast milk and local anaesthetic eye 
drops15–17. It is highly beneficial to test whether morphine adminis-
tration reduces acute pain caused by ROP screening and whether 
it improves clinical stability during the subsequent 24 hours. 
While the primary objective of this study is to look at the effect of 
morphine analgesia on well-validated clinical pain scores calcu-
lated 30 seconds after ROP screening, this study also provides an 
opportunity to gain a mechanistic insight into how morphine alters 
nociceptive brain and spinal cord activity evoked by an acute 
noxious heel lance. If a bolus dose of oral morphine is proven to 
be a safe and effective analgesic for procedural pain that results in 
improved clinical stability, this would result in a significant change 
to current clinical practice for ROP screening and, potentially, 
provide an analgesic which can be used for other acutely painful 
procedures in infants, such as laser eye surgery.
A single dose of 200 μg/kg oral morphine sulphate (which is 
double the dose proposed in this study) has been used in a pre-
vious study testing analgesic efficacy for ROP screening and the 
authors reported, in the paper and through personal communica-
tion, that there were no adverse effects of morphine administration 
at this dose37.
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Morphine analgesia will be administered in addition to current 
pain management strategies, which, in the John Radcliffe Hospi-
tal, include the use of local anaesthetic eye drops prior to the ROP 
screening and comfort techniques (such as swaddling) during heel 
lancing. Other than the administration of the trial medication and 
some extra physiological monitoring, current clinical practice will 
not be altered for trial participants.
In this trial we will use a standardised comfort technique. Trial 
participants will be swaddled using methods that we have success-
fully implemented in previous electroencephalography (EEG) and 
Magnetic Resonance Imaging (MRI) studies. We will lay the infant 
supine on a cotton cloth and cross the infant’s arms over their chest 
in a relaxed position. The ends of the cloth will then be crossed 
over the infant’s body and arms, and tucked beneath the opposing 
side. The swaddling cloth will not cover the infant’s feet, in order 
to allow access for monitoring leads and blood sampling. The cloth 
will only restrict gross upper body movements and hold the infant 
securely and comfortingly in a flexed position.
Outline of trial proposal
In this study we aim to determine whether a single dose of 
morphine sulphate (100 μg/kg) administered orally prior to pain-
ful clinical procedures provides effective analgesia. The dosage, 
route of administration and time course have been selected based 
on previous literature37 and based on recommendations in the 
British National Formulary for children (BNFc) (2015).
The primary objective is to determine whether morphine analgesia 
reduces clinical pain scores following ROP screening. In addition, 
to provide a better mechanistic understanding of how morphine 
affects nociceptive brain and spinal cord activity we will investigate 
the effect of morphine on electrophysiological measures of nocic-
eptive brain and spinal cord activity evoked by a heel lance. Infants 
will be randomised to receive either morphine or a placebo prior 
to a clinically required heel lance and ROP screening, which will 
be performed on the same test occasion. The effect of morphine on 
clinical pain scores (evoked by the heel lance and ROP screening), 
nociceptive-specific brain activity and spinal cord activity (evoked 
by clinical heel lance), clinical stability, and drug safety will be 
investigated (Figure 1).
Trial design
Trial description
This study is a clinical trial of an investigational medicinal 
product (IMP). It is a single-centre double-blind randomised 
placebo-controlled study investigating whether morphine sulphate 
provides effective analgesia compared with a placebo (inactive 
Box 1. Objectives and Outcome Measures
Objectives Outcome Measures
Primary Objective 
(i)    To test whether administration of morphine reduces clinical 
pain scores (PIPP-R) 30 seconds after ROP screening 
compared with a placebo (inactive solution).
Primary Outcome Measure 
(i)   PIPP-R score 30 seconds after ROP screening.
Co-primary Objective 
(ii)    To test whether administration of morphine reduces 
nociceptive-specific brain activity following a clinically-
essential heel lance compared with a placebo (inactive 
solution).
Co-primary Outcome Measure 
(ii)    Magnitude of nociceptive-specific brain activity evoked by heel 
lance.
Secondary Objectives 
(iii)    To test whether administration of morphine improves clinical 
stability in the 6-hour and 24-hour period following the start 
of the clinical intervention. The clinical intervention is defined 
as the heel lance followed by ROP screening.
Secondary Outcome Measures 
(iii)    Clinical stability in the 6-hour and 24-hour period following 
the start of the clinical intervention. The clinical intervention is 
defined as the heel lance followed by ROP screening. (Clinical 
stability is assessed from pulse oximetry recordings and the 
need for increased respiratory support.)
(iv)    To test whether administration of morphine reduces clinical 
pain scores (PIPP-R) and reflex withdrawal activity following 
a clinically essential heel lance compared with a placebo 
(inactive solution).
(iv)    PIPP-R score and amplitude of reflex withdrawal following heel 
lance.
(v)    To test whether administration of morphine is safe by 
determining whether it results in episodes of respiratory 
depression or hypotension that require intervention.
(v)    Drug safety will be assessed by calculating the number of 
incidences of apnoea that require intervention using NeoPuff or 
‘bag and mask’ and the number of incidences of hypotension 
that require treatment with inotropes in the 24-hour period 
following the administration of the IMP or placebo.
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solution) for clinically required ROP screening and heel lancing 
(Figure 2).
Infants will be recruited during a 33-month period. Infant partici-
pants will be studied on a single test occasion while they are in 
hospital, when they require ROP screening and a clinical heel lance 
on the same occasion. No extra blood tests or noxious procedures 
will be performed for the purpose of the study. Participants will be 
included in the study for a 48-hour period. This will be 24-hours 
before and after the start of the clinical intervention. The clini-
cal intervention is defined as the heel lance followed by the ROP 
screening. The start of the clinical intervention is therefore defined 
as the time when the heel lance is performed.
Participant identification
Trial participants and study feasibility
6500 infants are born at the John Radcliffe Hospital each year and 
700 are admitted to the neonatal unit. ROP screening is performed 
on approximately 100 infants per year and on average these infants 
will receive two ROP exams while they are in-patients. The majority 
of infants will require routine blood tests prior to the ROP screen-
ing and, based on previous studies we expect a recruitment consent 
success rate of approximately 60%.
Each week the Ophthalmologists perform up to 10 ROP screening 
examinations in the neonatal unit. Of these we expect that approxi-
mately 3 examinations would be conducted on infants who are 
eligible for inclusion in the trial. In our previous study32, which 
used a similar design (with an active and placebo arm) the paren-
tal consent rate was 66% (62 out of 94 infants were success-
fully recruited). To keep to our proposed recruitment schedule 
(156 infants in 33 months), on average, we need to recruit just 
over 1 baby per week. This equates to a parental consent rate of 
approximately 30%, which we consider to be realistic and highly 
achievable.
We plan to study 1–2 infants per week and intend to study 156 
infants in total, suggesting that it is feasible that the data is collected 
for this trial within 2 years and 9 months. We expect to approach 
approximately 400 parents and will not study any individual baby 
more than once.
Inclusion criteria
• Participants will be in-patients on the neonatal unit at the 
John Radcliffe Hospital, Oxford.
• Infants born less than 32 weeks’ gestation or birth weight 
less than 1501 g.
• At the time of study, infants will be between 34 and 
42 weeks gestational age (GA) and will be studied if 
they require a clinical heel lance and ROP screening on 
the same test occasion. We will study infants during a 
single test occasion when they are greater than or equal 
to 34 weeks’ gestation.
• Infants for whom parents/guardians have given written 
informed consent for inclusion in the trial.
• Senior clinician considers inclusion in trial to be medically 
appropriate.
Exclusion criteria
• intraventricular haemorrhage (IVH) > grade II
• short bowel syndrome
• receiving nil by mouth due to documented gut pathology
• received opiates in the last 72 hours
• received other analgesics or sedatives in the last 24 hours
• previously documented episode of morphine sensitivity
• congenital malformation or genetic condition known to 
affect neurological development
• born to mothers who regularly used opiates during 
pregnancy or while breastfeeding or expressing breast 
milk.
+10 minutes +24 hours
 Topical local
  anaesthetic given
 Study start
 Morphine/placebo
  intervention
 ROP screening  Study end Heel lance control  Heel lance
s0.1s5.0-s5.0- 1.0s
s5.1s5.1s0.1- -1.0s
s03s03s51- s03s51-s51- PIPP (Video, SpO2, HR)
 Reflex limb withdrawal (EMG)
 Evoked potential (EEG)
 Monitoring clinical stability (SpO2, HR, Oxygen requirement, BP)
-2 minutes-24hrs -1 hour 0
Figure 1. Summary of the experimental protocol. The clinical intervention is defined as the heel lance followed by the ROP screening. All 
timings are approximate and are in relation to the start of the clinical intervention (i.e. the heel lance).
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Inclusion Criteria
Participants will be in-patients on the 
neonatal unit at the John Radclie Hospital, 
Oxford; born < 32 weeks’ gestation or birth 
weight < 1501 g; between 34 and 42 weeks 
gestational age (GA) at the time of study; 
require a clinical heel lance and ROP 
screening on the same test occasion; 
parents/guardians have given written 
informed consent for inclusion in the trial; 
senior clinician considers inclusion in trial to 
be medically appropriate.
Exclusion Criteria
IVH > grade II; short bowel syndrome; 
receiving nil by mouth due to documented 
gut pathology; received opiates in the last 
72 hours or other analgesics/ sedatives in 
the last 24 hours; previously documented 
episode of morphine sensitivity; born with a 
congenital malformation or genetic condi-
tion known to aect neurological develop-
ment; born to mothers who regularly use 
opiates during pregnancy or while breast-
feeding or expressing breast milk.
Active Intervention (n=78)
Morphine sulphate 
100 µg/kg
Inactive Intervention (n=78)
Placebo (inactive solution)
Randomisation (1:1 allocation ratio)
Web-based randomisation hosted by NPEU Clinical Trials Unit
24 hour Baseline Data Collection
(heart rate, oxygen saturation, blood pressure, oxygen requirement)
Clinically-essential noxious stimulation and innocuous control stimulation
(heel lance control, heel lance, ROP screening)
Primary Outcome measures
(i)    Premature infant pain prole - Revised (PIPP-R) score 30 seconds after ROP screening.
(ii)   Magnitude of nociceptive-specic brain activity evoked by heel lance.
Secondary Outcome measures
(iii)  Clinical stability in the 6-hour and 24-hour period after the start of the clinical intervention.
(iv)  PIPP-R score and amplitude of reex withdrawal following heel lance.
(v)   Number of incidences of apnoea that require intervention using NeoPuff or ‘bag and
        mask’ and number of incidences of hypotension that require treatment with inotropes in          
        the 24-hour period following the administration of the IMP or placebo.
Figure 2. Trial flowchart.
Trial procedures
Recruitment
The clinical team will identify infants who are eligible for inclu-
sion in the study shortly after birth and the infant’s parents will be 
informed about the study. Parents who are interested in the study 
will be given the opportunity to ask questions and will be given a 
Parent Information Leaflet (PIL). Once an ROP screening appoint-
ment has been confirmed in infants between 34 and 42 weeks gesta-
tion (which will be at least two weeks after they have been born), 
parents will be asked by members of the research team if they 
would like to give informed consent for their infant to take part in 
the study.
Informed consent
Written consent will be sought from the parents after they have 
been given a full verbal and written explanation of the trial. Written 
explanation will be given via the Parent Information Leaflet (PIL). 
Parents who do not speak English will only be approached if an 
adult interpreter is available. Relatives will not interpret.
Written informed parental consent will be obtained by means 
of dated parental signature and the signature of the person who 
obtained informed consent; this will be the Principal Investigator 
(PI) or healthcare/research professional with delegated authority. 
A copy of the signed informed consent form (ICF) will be given to 
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the parent(s). A further copy will be retained in the infant’s medi-
cal notes, a copy will be retained by the PI, and the original will be 
stored with the study data.
Enrolment
After informed consent has been obtained, the information will be 
entered onto the randomisation website. Infants will be considered 
enrolled into the Poppi trial once they have been given a study 
number.
Remuneration
Neither trial participants nor their parents will be given financial or 
material incentive or compensation to take part in this trial.
Randomisation
Randomisation of participants to receive either morphine sulphate 
or placebo (inactive solution) will be managed via a secure web-
based randomisation facility hosted by the National Perinatal 
Epidemiology Unit Clinical Trials Unit (NPEU CTU) at The 
University of Oxford. Participants will have a roughly equal chance 
of receiving morphine sulphate or placebo (inactive solution). 
The randomisation program will use a minimisation algorithm to 
ensure approximate balance between the groups with respect to 
gestational age at the time of study, gestational age at birth, number 
of days on a ventilator, presence of gastric tube at time of study, 
number of days since morphine has been given, intra-uterine 
growth restriction and previous surgery. The users of the system 
will have no insight into the next allocation. Balance between the 
groups for each of the minimisation variables will be reviewed 
by the Data Monitoring Committee (DMC) and reported in trial 
publications.
Participants will be randomised shortly before the 48-hour period 
of clinical stability monitoring commences. If any of the exclusion 
criteria manifest after consent but prior to randomisation, partici-
pants will not be randomised and therefore not included in the trial. 
If exclusion criteria manifest in the first 24 hours of clinical stability 
monitoring the investigational medicinal product (IMP) or placebo 
will not be administered and the infant withdrawn from the trial. In 
this case the infant will still be considered a trial participant.
A Senior Trials Programmer at the NPEU CTU will write the 
randomisation program and hold the code. In the event of an 
emergency, a participant may be unblinded by logging in to the 
randomisation website using a single-use access code provided in 
a sealed envelope. The reason for unblinding must be recorded. 
Clinicians carrying out emergency unblinding must be satisfied 
that it is a genuine emergency and that knowledge of the treatment 
allocation (either morphine or placebo) is needed to guide the 
appropriate clinical management of the participant. In some cases 
this may be achieved without unblinding by treating the participant 
as if they have received morphine sulphate solution.
Blinding
This will be a blinded study. Each individual IMP pack will 
contain 10ml amber glass bottle with tamper evident cap contain-
ing either morphine sulphate or placebo (inactive solution) and a 
sterile oral/enteral 3ml syringe. They will be labelled with a ran-
domisation code and will be indistinguishable by colour, smell 
and flow during administration. The packaging for both morphine 
sulphate and placebo will be identical. Once an infant is recruited 
into the trial, they will receive a single dose of morphine or 
placebo. The IMP packs will be stored in the study-specific drug 
cabinet in the neonatal unit.
When the study has officially ended and the data analysis is 
complete the randomisation code will be released to the primary 
researchers and statistician so that the treatment groups can be 
correctly identified. Thus, throughout the study all of the pri-
mary researchers, outcome assessors, parents and infants will be 
blinded to the identities of the solutions.
Trial design summary
Each recruited infant will participate in the trial for 48 hours, and 
will not require further follow-up. Once recruited, we will estab-
lish when the ROP screening is to be conducted and the stud-
ies will be timed to fit in with the Ophthalmology schedule. The 
Consultant Ophthalmologist is fully informed about this study 
and has agreed to liaise with the research team regarding timing 
of the ROP screening. Infants will be randomised to receive a sin-
gle dose of 100 μg/kg morphine sulphate or placebo, administered 
orally or via a gastric tube.
The IMP will be provided in individual 10ml amber glass bottles 
containing morphine sulphate (or inactive solution) at a concentra-
tion of 200 μg/ml and will be administered orally or via a gastric 
tube using a syringe 60 minutes before the heel lance is undertaken. 
The volume of solution administered to each infant will be calcu-
lated based on the infant’s working weight at the time of the study.
60 minutes before the heel lance (and after randomisation) infants 
will be administered either morphine sulphate or a placebo. Once 
the drug has been administered the research team will set up the 
electroencephalography (EEG), electromyography (EMG) and 
video monitoring. When the drug has reached maximum efficacy 
(which is approximately 60 minutes after administration) a clinical 
heel lance and heel lance control stimuli (where the lancet is rotated 
such that on release the blade does not touch the foot) will be per-
formed. During each procedure nociceptive-specific brain activity 
(measured using EEG), reflex withdrawal activity (measured using 
EMG on the biceps femoris of each leg), physiological activity 
(including oxygen saturation and heart rate) and facial expression 
change will be recorded.
After the heel lance has been completed, routine ROP screening 
will be carried out by an Ophthalmologist or appropriately trained 
Ophthalmology Trainee. The time taken for the screening to be per-
formed will be recorded.
Once the ROP screening is complete, pulse oximetry, oxygen 
requirement and blood pressure will continue to be monitored and 
recorded by our data logging equipment for 24 hours after the start 
of the clinical intervention (heel lance followed by ROP screen-
ing). Clinical stability of the infants will be assessed throughout 
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the 48-hour trial period. These measures will be calculated from 
pulse oximetry recordings and requirement for respiratory support. 
Pulse oximetry data will be monitored and downloaded to our data 
logging equipment for 24 hours before and 24 hours after the start 
of the clinical intervention (heel lance followed by ROP screen-
ing). Throughout the 48-hour trial period, blood pressure will be 
monitored 6 hourly and changes in respiratory support (including 
type of respiratory support modality and oxygen requirement) will 
be recorded.
Heel lance procedure
Infants will only be given a heel lance during routine investigations 
when blood samples are clinically required. Given the frequency 
with which blood samples are required in premature infants, the 
heel lance can be timed to occur immediately before the ROP 
screening. The heel lancet will be linked electronically to the record-
ing equipment, using methods that have been used in previous 
studies30–32. This methodology provides an opportunity to record the 
precise timing of when the heel lance occurs without interfering 
with clinical practice.
Retinopathy of prematurity (ROP) screening
All infants born at less than 32 weeks gestation or with a birth 
weight less than 1501 g are screened for ROP (UK Retinopathy 
of Prematurity Guidelines, 2008). The decision to conduct ROP 
screening will be independent of the trial. National and local policy 
guidelines will be followed to determine when screening will be 
performed (UK Retinopathy of Prematurity Guidelines, 2008). An 
Ophthalmologist or suitably experienced Ophthalmology Trainee 
will carry out screening as per standard practice. Both pupils will 
be dilated with mydriatic eye drops (Tropicamide 1% and Phenyle-
phrine 2.5%) approximately 1 hour prior to screening. At the time of 
screening, an assistant will support the infant’s head. Topical local 
anaesthetic (proxymetacaine 0.5%) instillation will be followed 
10 seconds later by insertion of an eyelid speculum, which will 
be used to hold the eyelid open during the exam. The eye will be 
intermittently lubricated using sterile saline drops. A Flynn style 
indenter will be used to stabilise the eye allowing for a standard-
ised intensity light beam to enter the eye through a condensing 
lens as part of the binocular ophthalmoscopic fundus examination. 
The right eye will be examined first followed by removal of the 
speculum and insertion into the left eye to repeat the process.
Recording techniques
We will use a range of techniques (listed in Table 1) to character-
ise the responses to noxious stimulation. Some of these measures 
will not be an additional burden for the infants as they are con-
tinuously recorded as part of their routine clinical care (i.e. pulse 
oximetry).
Electroencephalography (EEG). Electrophysiological activity will 
be acquired with the SynAmps RT 64-channel headbox and amplifi-
ers (Compumedics Neuroscan), with a bandwidth from DC - 400 Hz 
and a sampling rate of 2 kHz. CURRYscan7 neuroimaging suite 
(Compumedics Neuroscan) will be used to record the activity. All 
equipment will conform to the electrical safety standard for medi-
cal devices, IEC 60601–1. Eight EEG recording electrodes will 
be positioned on the scalp at Cz, CPz, C3, C4, FCz, T3, T4 and 
Oz according to the modified international 10–20 System. Refer-
ence and ground electrodes will be placed at Fz and the forehead 
respectively. EEG conductive paste will be used to optimise 
contact with the scalp. All impedances will be reduced to approxi-
mately 5 kΩ by rubbing the skin with EEG preparation gel prior 
to electrode placement. An ECG electrode will be placed on the 
left clavicle and a movement transducer will be placed on the 
abdomen to record respiration.
Electromyography (EMG). Bipolar EMG electrodes (Ambu Neu-
roline 700 solid gel surface electrodes) will be placed on the biceps 
femoris of each leg to measure reflex withdrawal. EMG will be 
recorded before and after the heel lance control and the heel lance 
stimuli.
Clinical pain scores. Clinical pain scores will be calculated using 
the validated Premature Infant Pain Profile - Revised (PIPP-R). 
PIPP-R is a composite measure encompassing behavioural, physi-
ological and contextual indicators involved in the pain response. 
These include gestational age, behavioural state, heart rate, oxygen 
saturation, and duration of brow bulge, eye squeeze, and nasolabial 
furrow. Each indicator in the PIPP-R is rated on a 4-point scale 
(0, 1, 2, and 3); these are summed together to produce a maximum 
possible score of 21. In the recently revised PIPP-R, the scores for 
the contextual indicators (gestational age and behavioural state) 
are only included if a non-zero score is recorded for either the 
physiological or behavioural variables26.
Table 1. Techniques used to characterise infant behaviour and physiology
Procedures Recording Methods Measurement
1 Electroencephalography (EEG) Nociceptive-specific brain activity
2 Electromyography (EMG) Reflex withdrawal
  3 * Pulse Oximetry Heart rate
 4 * Pulse Oximetry Oxygen saturation
5 Video recording Facial expression change
 6 * Blood pressure monitor Blood pressure
 7 * Oxygen flow meter (if required) Oxygen requirement
Note: (*) starred procedures are monitored as part of routine clinical care
Page 9 of 24
Wellcome Open Research 2016, 1:7 Last updated: 15 MAY 2019
Videos of facial expression will be recorded throughout the proce-
dures and scored offline from single frames using the PIPP-R facial 
coding system. Changes in heart rate and oxygen saturation will 
be downloaded from the pulse oximeter and used to calculate the 
PIPP-R score.
Heart rate, oxygen saturation and facial expression will be recorded 
in the 15-second period before and 30-second period after the heel 
lance and heel lance control. These measures will also be recorded 
in the 15-second period before ROP screening and in a 30-second 
period after ROP screening has been completed25,26.
Pulse oximetry. Heart rate and oxygen saturation will be meas-
ured throughout the 48-hour study period and downloaded to a 
computer. These data will be used to calculate the clinical pain 
scores following the heel lance and ROP screening and to assess 
clinical stability during the 6-hour and 24-hour after the start of 
the clinical intervention. (The clinical intervention is defined 
as the heel lance followed by ROP screening.) Data will be ana-
lysed offline and the number of clinically relevant episodes will be 
calculated based on the following definitions: 
• an episode of bradycardia will be defined as a pulse 
rate < 100 beats/min for at least 15 s
• an episode of tachycardia will be defined as a pulse 
rate > 200 beats/min for at least 15 s
• an episode of desaturation will be defined as oxygen 
saturation < 80% for at least 10 s
• an episode of apnoea will be defined as the cessation 
of respiratory air flow for at least 20 s
 Episodes of artefact (i.e. infant handling or essential clinical 
procedures) will be documented throughout the recordings.
Blood pressure monitoring. Blood pressure will be monitored 
6-hourly during the 24-hour period before and after the start of the 
clinical intervention. (The clinical intervention is defined as the 
heel lance followed by ROP screening.) This will be measured 
using a standard blood pressure cuff.
Increased respiratory support. Any change in respiratory support 
modality or a significant change in oxygen requirement will be 
documented during the 24-hour period before and after the start of 
the clinical intervention. (The clinical intervention is defined as the 
heel lance followed by ROP screening.)
Increased respiratory support will be defined as a significant 
increase in oxygen requirement or an increase in ‘respiratory sup-
port modality’.
Respiratory support modality is classified on a graded scale from 
1–4, according to the following definitions.
 Grade 1:  self-ventilating in air
 Grade 2:    low flow (0.01–0.35 litres/minute; 100% 
oxygen)
 Grade 3:   high flow (1–8 litres/minute) or continuous 
positive airway pressure (CPAP) or duoPAP 
(21–100% oxygen)
 Grade 4:  ventilator (21–100% oxygen)
If an infant has a change in ‘respiratory support modality’ that 
results in an increase in grade, this will count as an increase in res-
piratory support. 
A significant increase in oxygen requirement is defined as an 
increase in oxygen supply by more than 10%, a flow rate change of 
more than 1 litre/minute (if receiving high flow therapy) or a flow 
rate change of more than 0.04 litres/minute (if receiving low flow 
oxygen).
Measures of clinical stability. Clinical stability will be assessed 
based on the following measures (calculated in the 6-hour and 
24-hour period before and after the start of the clinical interven-
tion): number of episodes of bradycardia; number of episodes 
of tachycardia; number of episodes of desaturation; number of 
episodes of apnoea; and number of infants that required an increase 
in respiratory support.
Outcome measures
Premature Infant Pain Profile - Revised (PIPP-R) scores. Pain 
scores will be calculated using the Premature Infant Pain Profile- 
Revised (PIPP-R) scoring system25. PIPP-R scores will be cal-
culated on three occasions: (i) during the heel lance control 
procedure; (ii) during the heel lance procedure; and (iii) 30-seconds 
after the ROP screening (it is not possible to accurately calculate 
PIPP-R scores during ROP screening because the eyes are held 
open by a speculum). An interim analysis will be conducted once 
data has been collected from 50% of the trial participants. 20% of 
PIPP-R scores will be re-calculated by two investigators to ensure 
inter-rater and intra-rater reliability. Inter-rater and intra-rater 
reliability will also be calculated in 20% of trial participants once 
all data has been collected.
Nociceptive-specific brain activity. Nociceptive-specific brain 
activity evoked by a clinical heel lance has been well character-
ised in previous studies30–32. In this study we will investigate 
whether morphine administered prior to a clinically-required heel 
lance reduces the nociceptive-specific brain activity compared to a 
placebo (inactive solution). A mathematical template based on the 
Principal Component (PC) that reflects the nociceptive-specific 
activity in infants has been defined in an independent data set. The 
nociceptive-specific template will be projected onto the EEG data 
recorded in the 1000 ms period following each heel lance and heel 
lance control stimulus and the relative weight of the component 
calculated for each infant. A greater weight indicates a stronger 
noxious-specific evoked response. The response to the heel lance 
control stimulus is being recorded so that we can confirm that the 
brain activity evoked by the heel lance is noxious. This forms an 
important data quality control check30.
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Reflex withdrawal. The reflex withdrawal response will be 
characterised and the effect of treatment considered. The EMG 
data will be high pass filtered at 10 Hz and low pass filtered at 
500 Hz. The data will be baseline corrected to the pre-stimulus 
mean and the root mean square (RMS) of the signal calculated in 
250 ms windows37. The average root mean squared (RMS) value 
will be calculated in the 500 ms pre-stimulation and in the 1000 ms 
post-stimulation32,38.
Clinical stability. Clinical stability will be assessed based on 5 
clinical stability measures calculated in the 6-hour and 24-hour 
period before and after the start of the clinical intervention. (The 
clinical intervention is defined as the heel lance followed by 
ROP screening.) The following outcome measures will be 
calculated: number of episodes of bradycardia; number of 
episodes of tachycardia; number of episodes of desaturation; 
number of episodes of apnoea; and number of infants that required 
an increase in respiratory support.
Safety of administration of this dose of oral morphine. 
The final objective of this study is to establish whether the 
administration of this dose of oral morphine is safe.
This will be established by calculating the number of incidences of 
apnoea that require intervention using NeoPuff or ‘bag and mask’ 
and the number of incidences of hypotension that require treatment 
with inotropes in the 24-hour period following the administration of 
the IMP or placebo. This information will contribute considerably 
to the safety profile of oral morphine in neonatal patients.
Procedure for unblinding
In the event of an emergency, a participant may be unblinded by 
the clinician at site by logging in to the randomisation website 
using a single-use access code provided in a sealed envelope. 
The reason for unblinding must be recorded. Clinicians carrying 
out emergency unblinding must be satisfied that it is a genuine 
emergency and that knowledge of the treatment allocation (either 
morphine or placebo) is needed to guide the appropriate clinical 
management of the participant. In some cases this may be achieved 
without unblinding by treating the participant as if they have 
received morphine sulphate solution.
As it is best practice to not unblind participants until any follow-up 
is completed, all other requests for unblinding must be made in 
writing to the NPEU CTU, who along with Chief Investigator and 
Principal Investigator will consider the request.
Withdrawal from the intervention
Parent(s) may withdraw their infant from the intervention at any 
time and they are not obliged to give a reason. If parents choose to 
withdraw their child after the IMP or placebo (inactive solution) 
has been administered, they will be asked whether data already 
collected may be retained and used for the purposes of the trial. 
Parents will be made aware that this decision has no impact on any 
aspects of their infant’s continuing care.
The attending clinician may withdraw the infant from treatment if 
they consider this to be in the best interest of the infant’s health and 
well-being. If any of the exclusion criteria manifest in the 24 hours 
of clinical stability monitoring prior to the administration of the 
IMP or placebo then the infant will be withdrawn from the trial.
Definition of end of trial
The end of the trial will be defined as the date when the trial 
database is locked. An end of trial declaration will be made to 
MHRA and the approving REC.
Investigational Medicinal Product (IMP)
Description of IMP and placebo
The IMP is morphine sulphate prepared in a carrier solution so that 
it is suitable for oral administration in infants. The placebo contains 
the carrier solution without the morphine sulphate. The IMP and 
placebo must be stored at a temperature of 25°C or below.
Individual identical 10ml glass amber bottles with tamper evident 
cap containing either morphine sulphate or placebo (inactive 
solution) will be labelled with a pack ID and will be indistinguisha-
ble by colour, smell and flow during administration. The secondary 
packaging will contain a single use sterile oral/enteral 3ml syringe 
and will be labelled with a pack ID. The morphine sulphate will be 
supplied at a concentration of 200 μg/ml, in a dose of 100 μg/kg. 
This dose has been selected based on recommendations in the BNFc 
(British National Formulary for children (2015)).
Preparation
The IMP and placebo (inactive solution) will be manufactured 
by Stockport Pharmaceuticals Production Unit in accordance with 
Good Manufacturing Practice (GMP).
Distribution
The IMP will be delivered to the Hospital Pharmacy at the John 
Radcliffe Hospital.
Storage of IMP and placebo (inactive solution)
The trial medication will be stored in the study-specific locked 
drug cabinet in the Neonatal Unit.
Accountability
The drugs will be allocated by the central randomisation system 
and will be recorded by NPEU CTU and the Neonatal Unit 
Pharmacist. A record of the individual administrations and drug 
accountability will be kept.
Studies will be conducted on the Neonatal Unit where specialist 
doctors and nurses are present at all times. Resuscitation equipment 
is available if necessary, including naloxone (an antagonist for 
morphine).
Destruction
The volume of the IMP or placebo to be discarded will be 
disposed of as per local trust policy. It will be rendered irretrievable 
by emptying the precise calculated volume for destruction into a 
sharps bin. This process will be witnessed by a second qualified 
clinical staff member. The volume discarded will be clearly 
documented by the clinician undertaking the destruction and the 
witness. The syringe, once emptied during IMP administration, 
will then also be discarded in the sharps bin. In the event that 
the IMP reaches its expiry date before use, it will be retrieved by 
pharmacy and destroyed as per trust protocol.
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Concomitant medication
Current clinical protocols regarding drug administration on the 
Neonatal Unit will not be altered by this study (apart from the 
additional trial medication). At present infants do not receive any 
pain medication prior to heel lancing so it is acceptable that the 
control group receive a placebo (inactive solution) with no medici-
nal effects. After the heel lance, and approximately 10 seconds 
before the ROP screen, all infants will receive 0.5% proxymeta-
caine local anaesthetic in each eye, following standard clinical 
practice. In addition, approximately 1 hour prior to the ROP screen, 
all infants will also receive mydriatic eye drops to evoke pupil 
dilation. The infants may be receiving medication for other condi-
tions and the attending clinician will confirm that participation in 
the trial is not contraindicated.
Safety reporting
Causality
The relationship of each adverse event to the trial medication must 
be determined by a medically qualified individual according to the 
following definitions:
• Unrelated – where an event is not considered to be 
related to the IMP.
• Possibly – although a relationship to the IMP cannot 
be completely ruled out, the nature of the event, the 
underlying disease, concomitant medication or temporal 
relationship make other explanations possible.
• Probably – the temporal relationship and absence of a 
more likely explanation suggest the event could be related 
to the IMP.
• Definitely – the known effects of the IMP, its therapeutic 
class or based on challenge testing suggest that the IMP 
is the most likely cause.
 All AEs (SAEs) labelled possibly, probably or definitely will 
be considered as related to the IMP.
Procedures for recording adverse events
The following are adverse events that could be reasonably foreseen 
to occur in this population of infants during the course of this trial 
and do not require recording.
• Suspected sepsis (requiring up to 36 hours antibiotics)
• Anaemia
Box 2. Safety Reporting Definitions
Adverse Event (AE) Any untoward medical occurrence in a participant to whom a medicinal product has been 
administered, including occurrences which are not necessarily caused by or related to that product.
Adverse Reaction (AR) An untoward and unintended response in a participant to an investigational medicinal product which 
is related to any dose administered to that participant. 
The phrase “response to an investigational medicinal product” means that a causal relationship 
between a trial medication and an AE is at least a reasonable possibility, i.e. the relationship cannot 
be ruled out. 
All cases judged by either the reporting medically qualified professional or the Sponsor as having a 
reasonable suspected causal relationship to the trial medication qualify as adverse reactions.
Serious Adverse Event (SAE) A serious adverse event is any untoward medical occurrence that: 
• results in death 
• is life-threatening 
• requires inpatient hospitalisation or prolongation of existing hospitalisation 
• results in persistent or significant disability/incapacity 
• consists of a congenital anomaly or birth defect. 
Other ‘important medical events’ may also be considered serious if they jeopardise the participant or 
require an intervention to prevent one of the above consequences. 
NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event; it does not refer to an event which 
hypothetically might have caused death if it were more severe.
Serious Adverse Reaction (SAR) An adverse event that is both serious and, in the opinion of the reporting Investigator, believed with 
reasonable probability to be due to one of the trial treatments, based on the information provided.
Suspected Unexpected Serious 
Adverse Reaction (SUSAR)
A serious adverse reaction, the nature and severity of which is not consistent with the information 
about the medicinal product in question set out: 
• in the case of a product with a marketing authorisation, in the summary of product characteristics 
(SmPC) for that product 
• in the case of any other investigational medicinal product, in the investigator’s brochure (IB) relating 
to the trial in question.
NB: to avoid confusion or misunderstanding of the difference between the terms “serious” and “severe”, the following note of clarification 
is provided: “Severe” is often used to describe intensity of a specific event, which may be of relatively minor medical significance. 
“Seriousness” is the regulatory definition supplied above.
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• Minor changes in oxygen requirement (i.e. an increase 
in oxygen supply by less than 10%, a flow rate change 
of less than 1 litre/minute (high flow machine) or a flow 
rate change of less than 0.04 litres/minute (low flow 
machine)
• Electrolyte disturbances
All other AEs occurring during the 24 hour period following the 
administration of the IMP or placebo that are observed by the 
Investigator, will be recorded on the Case Report Form (CRF), 
whether or not attributed to trial medication.
The following information will be recorded: description, time and 
date of onset, severity, assessment of relatedness to trial medica-
tion, other suspect drug or device and action taken. Follow-up 
information should be provided as necessary.
The severity of events will be assessed on the following scale: 
1 = mild, 2 = moderate, 3 = severe.
AEs considered related to the trial medication as judged by a 
medically qualified investigator or the Sponsor will be followed up 
either until resolution, or the event is considered stable.
It will be left to the Investigator’s clinical judgment to decide 
whether or not an AE is of sufficient severity to require intervention 
and or removal from the trial. If this occurs, the participant will be 
given medical supervision until symptoms cease, or the condition 
becomes stable.
Reporting procedures for serious adverse events
Foreseeable serious adverse events. The following are serious 
adverse events that could be reasonably foreseen to occur in this 
population of infants during the course of this trial. They do not 
require expedited reporting by the trial centre as SAEs.
• Death (unless unforeseen)
• Necrotising enterocolitis (NEC) or focal intestinal 
perforation
• Intracranial abnormality (haemorrhage, parenchymal 
infarction, or focal white matter damage) on cranial 
ultrasound scan or other imaging
• Microbiologically-confirmed or clinically suspected 
late-onset invasive infection
• Retinopathy of prematurity
• Patent ductus arteriosus (requiring treatment)
• Congenital abnormalities
Reporting procedures for serious adverse events. Safety data as 
described in this section will be collected for 24 hours after the IMP 
or placebo is administered. All foreseeable SAEs will be recorded 
on the eCRF. SAEs that are not included in the list of foreseeable 
SAEs will be reported to NPEU CTU immediately, but at least 
within 24 hours of the research site becoming aware of the event. 
SAEs can be reported in one of the following ways: 
i) using the Clinical Database OpenClinica©, only staff 
with access to OpenClinica© may report SAEs in 
this way, site staff will be required to print off the 
OpenClinica© SAE form and obtain the information 
and signature of the Study Clinician carrying out the 
causality assessment. The completed signed SAE form 
must be emailed or faxed to NPEU CTU. NPEU CTU 
staff will automatically be informed via email of any 
SAE’s reported electronically.
ii) by completing an SAE form which is emailed or faxed 
to NPEU CTU. Paper copies will be available with 
the trial documentation to enable anyone to report an 
SAE.
NPEU CTU will ensure that the SAEs are assessed by the Chief 
Investigator (CI) or safety delegate and that review of the SAEs 
are timely, taking into account the reporting time for a potential 
SUSAR. If any additional information regarding the SAEs 
becomes available this will be detailed on a new SAE form and also 
emailed or faxed to NPEU CTU or reported electronically using 
OpenClinica©. If reporting electronically, the site must complete 
the information in OpenClinica© and arrange for it to be printed 
and signed by the Study Clinician making the causality assess-
ment. Guidance for the research site is provided on the paper SAE 
reporting form and contained within trial guidance documentation. 
All SAEs will be reviewed by the DMC after every 25 patients have 
been randomised and safety data collected (i.e. n=25, 50, 75, 100 
and 125). The CI will inform all investigators concerned of relevant 
information that could adversely affect the safety of participants.
Expectedness. Expectedness will be determined according to the 
Summary of Product Characteristics for Oramorph Oral Solution 
and will be assessed by a medically qualified investigator or 
suitably qualified delegate.
Suspected unexpected serious adverse reactions (SUSAR) reporting. 
All SUSARs will be reported by the CI or delegate to the relevant 
Competent Authority and to the REC and other parties as applica-
ble. For fatal and life-threatening SUSARs, this will be done no 
later than 7 calendar days after the Sponsor or delegate is first aware 
of the reaction. Any additional relevant information will be reported 
within 8 calendar days of the initial report. All other SUSARs will 
be reported within 15 calendar days.
Treatment codes will be unblinded for specific participants.
The Sponsor will inform all Principal Investigators of any SUSARs 
for the relevant IMP for all studies they are sponsoring, whether or 
not the event occurred in the current trial.
Development Safety Update Reports (DSURs)
The CI will submit (in addition to the expedited reporting above) 
DSURs once a year throughout the clinical trial, or on request, to 
the Competent Authority (MHRA in the UK), Ethics Committee, 
Host NHS Trust and Sponsor.
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Statistics and Analysis
Power calculation
The primary objective of this study is to determine whether 
morphine administration reduces clinical pain scores (PIPP-R) 
30 seconds after ROP screening in the infants administered 
morphine compared with infants administered a placebo (inac-
tive solution). The co-primary objective is to determine whether 
morphine administration reduces nociceptive-specific brain activ-
ity in response to a heel lance, compared with administration 
of a placebo. A 2-point reduction in PIPP scores is considered to 
be a clinically-meaningful reduction in pain38 and scores below 
7 are considered to reflect minimal pain25. Three studies have 
used PIPP scores to assess analgesic efficacy following ROP 
screening39–41. Using the most conservative data, where the mean 
PIPP score post ROP screening was 8.3 (standard deviation [SD] 
3.5), we would require 66 infants per group to observe a 2-point 
reduction in PIPP-R scores, with a power of 90% at a two-sided 
significance level of 0.05.
We also considered the sample size required to see a significant 
difference between the groups in the co-primary outcome meas-
ure (i.e. the nociceptive-specific brain activity evoked by a heel 
lance). In previous analysis33 the nociceptive-specific brain activity 
evoked by a heel lance had a mean amplitude of 0.2 (SD 0.14). In 
this study the amplitude of the nociceptive-specific brain activity 
will be calculated and compared between the two groups. Stud-
ies in adults with chronic pain indicate that morphine treatment 
attenuates the amplitude of laser-evoked potentials by 33.1%42 
Furthermore, adults administered Tramadol (an opioid treatment) 
show up to a 50% reduction in the amplitude of laser-evoked poten-
tials43. This reduction in nociceptive brain activity is coupled with 
the verbal report that tramadol is providing effective pain relief. 
Tramadol is a widely used as an analgesic in adults and trials have 
shown that it effectively reduces pain in patients with neuropathic 
pain44,45.
In this study we will assume that a 40% reduction in the 
magnitude of the nociceptive-specific brain activity represents a 
clinically meaningful reduction in brain activity, which in adults 
would be concomitant with a significant reduction in verbally 
reported pain scores. A 40% reduction would lead to the nox-
ious components having a post-treatment amplitude of approxi-
mately 0.12 (SD 0.14) down from a mean of 0.20. Coincidentally, 
we would require 66 infants per group for a power of 90% at a 
two-sided significance level of 5%. Allowing for a loss to follow-up 
rate of approximately 10% (i.e. due to technical difficulties during 
physiological monitoring), a total of 148 infants will need to be 
included in the study.
We anticipate the proportion of twins eligible for the trial to 
be around 25% based on past studies (e.g. NPEU-run BOOST-
II UK, I2S2, PiPS and SIFT trials). There is evidence that the 
correlation in pain outcomes between twins is 0.546. Hence the 
effect of clustering (technically the design effect) is calculated 
to be 1.06. This will inflate the total sample size required (90% 
power, 5% two-sided significance level, 10% loss to follow-up and 
accounting for multiple births) from 148 to 156 (78 per group).
Significance levels
For the analysis of the primary outcome measure and co-primary 
outcome measure, a P-value of 0.05 (two-sided 5% significance 
level) will be used to indicate statistical significance. We will 
address the multiplicity issue by using Hochberg’s procedures for 
multiple testing to control the family-wise error rate47. Therefore, 
we will reject the null hypothesis for both outcomes if P<0.05 for 
both outcomes. If P>0.05 for one of the outcomes then the other 
outcome will be tested at 2.5% significance level. This method is 
less stringent than the Bonferroni adjustment while preserving the 
original power of the study.
Comparisons of all other outcomes will be reported in full for 
completeness and transparency. For all other analyses, a P-value 
of 0.01 (two-sided 1% significance level) will be used to indicate 
statistical significance, in order to take account of the number 
of comparisons. Two-sided statistical tests and corresponding 
P-values will be presented throughout; however for the purposes 
of interpretation of results, confidence intervals will dominate, 
rather than P-values.
Missing data
Missing data may occur in our trial. For example, this could be 
due to equipment failure, artefacts within the EEG recording, or 
the infant being withdrawn if morphine administration is deemed 
clinically inappropriate after a participant has been randomised. 
If missing data does exist we expect it will occur at random, and 
so the collected data will be representative of the population. To 
account for missing data we have inflated our sample size by 10%. 
The analysis will be conducted using the available data.
Analysis
Primary and co-primary outcome measures analysis.
PIPP-R score 30 seconds after ROP screening PIPP-R scores (30 
seconds after ROP screening) in the morphine and placebo groups 
will be compared using linear regression to estimate the mean 
difference with 95% confidence interval. If the PIPP-R scores are 
skewed, we will present the median and interquartile range (or 
entire range, whichever is appropriate) for each group, and estimate 
the median difference between groups with corresponding 95% 
confidence interval.
Nociceptive-specific brain activity The projected weight of the 
template for the morphine and placebo groups will be compared 
using linear regression, depending on the mean and variance of 
the data. If appropriate, we will present the mean and standard 
deviation for each group and estimate the mean difference plus 
95% confidence intervals. If the outcome data are skewed, we 
will present the median and interquartile range (or entire range, 
whichever is appropriate) for each group, and estimate the median 
difference between groups with corresponding 95% confidence 
interval.
Secondary outcome measures analysis.
PIPP-R score following heel lance PIPP-R scores following 
heel lance in the morphine and placebo groups will be compared 
using linear regression to estimate the mean difference with 
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99% confidence interval. If the PIPP-R scores are skewed, we 
will present the median and interquartile range (or entire range, 
whichever is appropriate) for each group, and estimate the median 
difference between groups with corresponding 99% confidence 
interval.
Reflex withdrawal The average RMS activity in the 1000 ms 
post the heel lance for the morphine and placebo groups will be 
compared using linear regression, depending on the mean and 
variance of the data. If appropriate, we will present the mean and 
standard deviation for each group and estimate the mean difference 
plus 99% confidence interval. If the outcome data are skewed, we 
will present the median and interquartile range (or entire range, 
whichever is appropriate) for each group, and estimate the median 
difference between groups with corresponding 99% confidence 
interval.
Clinical stability analysis The number of episodes of bradycardia, 
tachycardia, desaturation, and apnoea; and the number of infants 
that required an increase in respiratory support that occur in the 
24-hour period after the start of the clinical intervention will be 
compared between the morphine and placebo groups. Depending 
on the distribution of these counts, either Poisson or linear regres-
sion will be used for these analyses to calculate the effect estimate 
plus 99% confidence interval. If appropriate, adjustment for the 
24 hour baseline period will be made. Alternatively, we will present 
the median and interquartile range (or entire range, whichever is 
appropriate) for each group and estimate the median difference 
between groups with corresponding 99% confidence interval. In 
the event of occurrences being very infrequent or the outcome 
of interest being the occurrence of increased respiratory support, 
logistic regression may be used as an alternative.
Safety analysis Drug safety will be assessed by measuring 
the number of occurrences of apnoea that require intervention 
via NeoPuff or ‘bag and mask’ and the number of episodes of 
hypotension that require treatment with inotropes in the 24-hour 
period after drug administration. The number of occurrences will be 
compared between the morphine and placebo groups. Depending 
on the distribution of these counts, either Poisson or linear regres-
sion will be used for these analyses to calculate the effect estimate 
plus 99% confidence interval. Alternatively, we will present the 
median and interquartile range (or entire range, whichever is appro-
priate) for each group and estimate the median difference between 
groups with corresponding 99% confidence interval. In the event of 
occurrences being very infrequent, logistic regression may be used 
as an alternative.
We currently use Stata/SE 13.1 for Windows for statistical analysis.
Data Management
Source data
Source documents are where data are first recorded, and from 
which participants’ case report form (CRF) data are obtained. 
These include, but are not limited to, hospital records (from which 
medical history and previous and concurrent medication may be 
summarised into the CRF), clinical and office charts, laboratory 
and pharmacy records, diaries, video footage acquired for the 
purpose of the trial, physiological data (e.g. EEG recordings, EMG 
recordings and other physiological data) and correspondence.
CRF entries will be considered source data if the CRF is the site of 
the original recording (e.g. there is no other written or electronic 
record of data). All documents will be stored safely in confidential 
conditions.
Access to data
Direct access will be granted to the research team, authorised 
representatives from the Sponsor, host institution and the regu-
latory authorities to permit trial-related monitoring, audits and 
inspections.
Data handling and record keeping
The CI will take overall responsibility for ensuring that each 
participant’s information remains confidential. All records will be 
stored securely and kept in strict confidence in compliance with 
the Data Protection Act. Minimal personal data will be collected 
and stored at NPEU CTU. Data collected will be stored in an elec-
tronic database in which the participant will be identified by a trial 
specific number. The infant’s name and any other identifying 
details will be stored separately and linked by the trial number. This 
information will be stored for a period of no less than 25 years in 
order to follow up health related issues that may become relevant 
in the future. After the trial has been completed and the reports 
published, the data will be archived in a secure physical or 
electronic location with controlled access.
Storage will be on a restricted area of a file server. The server is 
in a secure location and access is restricted to a few named indi-
viduals. Offices where data are stored are located in a secure area 
via an electronic tag and individual rooms are kept locked when 
unoccupied.
Data will be processed on a workstation by authorised staff. The 
computer workstations access the network via a login name and 
password (changed regularly). No data are stored on personal 
workstations. Backing up is done automatically overnight to an 
offsite storage area. The location of the backup computer is in a 
separate department.
Quality Assurance Procedures
The trial will be conducted in accordance with the current approved 
protocol, Good Clinical Practice (GCP), relevant regulations and 
standard operating procedures. The CI and PI, with the support 
of the Project Management Group (PMG) will be responsible for 
the day-to-day smooth running of the trial at the site. They will 
encourage recruitment, provide staff education and training, and 
monitor data completeness and quality. NPEU CTU will perform a 
trial risk assessment prior to commencement that will be reviewed 
at regular intervals during the course of the trial. The degree of 
central and site monitoring will be outlined in a separate Moni-
toring Plan, developed in light of any risks identified in the risk 
assessment. Site monitoring will be carried out by a suitably 
qualified person independent of the study team.
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Trial Governance
Project Management Group (PMG)
The trial will be supervised on a day-to-day basis by the Chief 
Investigator and (CI) Principal Investigator (PI) with the support of 
the PMG. This group reports to the Trial Steering Committee (TSC) 
which is responsible to the trial Sponsor.
• The PMG will meet regularly (at least monthly).
• The core PMG will consist of the following:
• NPEU CTU Director
• NPEU CTU Senior Trials Manager
• NPEU CTU Trial Co-ordinator
• NPEU CTU Statistician
• NPEU CTU Programmer
• Principal Investigator
• Chief Investigator
• Principal Research Scientist
• Principal Clinical Researcher
Trial Steering Committee (TSC)
The trial will be overseen by the TSC consisting of an independent 
chair and at least two other independent members.
Data Monitoring Committee (DMC)
A DMC independent of the applicants and of the TSC will review 
the progress of the trial after every 25 patients have been randomised 
and provide advice on the conduct of the trial to the TSC and (via 
the TSC) to the PMG. The DMC will act according to its Charter, 
which will be agreed at its first meeting.
The aims of the DMC will include: 
• To pick up any trends, such as increases in un/expected 
events, and take appropriate action
• To seek additional advice or information from investiga-
tors where required
• To evaluate the risk of the trial continuing and take 
appropriate action where necessary.
The DMC will monitor Safety outcomes very closely. Drug safety 
will be assessed by measuring the number of occurrences of 
apnoea that result in increase in respiratory support modality or 
require intervention via NeoPuff or ‘bag and mask’ or hypoten-
sion that require treatment with inotropes in the 24-hour period 
after drug administration. The DMC will review trial safety 
outcomes after every 25 patients have been randomised and safety 
data collected (i.e. n=25, 50, 75, 100 and 125). In addition, the 
Chief Investigator (or suitably trained delegate) will be notified of 
every such occurrence.
A formal sequential safety procedure will be applied and presented 
to the independent Data monitoring committee (DMC). We will 
employ a stopping boundary using group sequential methods with 
boundaries agreed by the DMC and specified in the DMC Charter. 
At each safety review performed by the DMC, a graph showing 
evidence of the relative safety of the treatments will be provided to 
act as a guide to the DMC members. If the pre-specified boundary 
is crossed, then the DMC should consider terminating the trial, 
taking into account other considerations (e.g. implications on 
future patients/clinical practice and follow-up, how convincing 
the evidence is, etc.).
An interim statistical analysis of the primary and secondary 
outcomes will be conducted once data has been collected from 
50% of trial participants (78 infants). In the light of the interim data 
analysis, and other evidence from relevant studies (including 
updated overviews of relevant randomised controlled trials), the 
DMC will inform the TSC, if in their view there is proof beyond 
reasonable doubt that the data indicate that any part of the protocol 
under investigation is either clearly indicated or contra-indicated. 
Guidelines for early cessation will be agreed with the DMC and 
documented in the DMC Charter.
Serious Breaches
The Medicines for Human Use (Clinical Trials) Regulations 
contain a requirement for the notification of “serious breaches” to 
the MHRA within 7 days of the Sponsor becoming aware of the 
breach.
A serious breach is defined as “A breach of Good Clinical Practice 
(GCP) or the trial protocol which is likely to affect to a significant 
degree – 
(a) the safety or physical or mental integrity of the subjects 
of the trial; or
(b) the scientific value of the trial”.
Incidents and protocol deviations will be reported as soon as 
possible to the NPEU CTU and assessed by the PMG. In the 
event that a serious breach is suspected the Sponsor must be 
contacted within 1 working day. In collaboration with the CI, the 
serious breach will be reviewed by the Sponsor and, if appropri-
ate, the Sponsor will report it to the REC committee, Regulatory 
authority and the NHS host organisation within seven calendar 
days.
Ethical and Regulatory Considerations
Declaration of Helsinki
The Chief Investigator will ensure that this study is conducted in 
accordance with the principles of the Declaration of Helsinki.
Guidelines for Good Clinical Practice
The Chief Investigator will ensure that this study is conducted in 
full conformity with relevant regulations and with the Guidelines 
for Good Clinical Practice.
Approvals
The trial will start after gaining approval from the MHRA and a 
Research Ethics Committee. Additionally, research governance 
approval of the host institutions will be sought.
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The CI or their delegate will submit and, where necessary, obtain 
approval from the above parties for any substantial amendments to 
the original approved documents.
Trial sponsor
The University of Oxford is the nominated sponsor for the 
trial.
Finance and Insurance
Funding
The Wellcome Trust and National Institute of Health Research, 
EME Programme is funding the trial.
Insurance
The University has a specialist insurance policy in place which 
would operate in the event of any participant suffering harm as a 
result of their involvement in the research (Newline Underwriting 
Management Ltd, at Lloyd’s of London). NHS indemnity operates 
in respect of the clinical treatment which is provided.
Publication Policy/Acknowledgement of Contribution
The Principal Investigator will co-ordinate dissemination of 
the results from this study. To safeguard the scientific integrity of 
the trial, data from this study will not be presented in public before 
the main results are published without the prior consent of the 
TSC.
The success of the trial depends on a large number of neonatal 
nurses, neonatologists, and parents. Credit for the study findings 
will be given to all who have collaborated and participated in the 
study.
All publications and presentations relating to the study will 
be authorised by the TSC. The first publication of the trial 
results will include as named authors, the Investigators, Statisti-
cian and Trial Co-ordinator. Members of the TSC and the DMC 
will be acknowledged and cited by name if published in a 
journal where this does not conflict with the journal’s policy. 
Authorship of secondary publications will be approved by the 
PI but will acknowledge the contribution of the TSC and the 
NPEU CTU.
Parents will be sent a summary of trial results; this will contain a 
reference to the full publication. A copy of the journal article will 
be available on request from NPEU CTU.
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This protocol describes a blinded randomised placebo-controlled trial investigating the efficacy of
morphine analgesia for procedural pain in infants.
In the description of the protocol all the elements are appropriately addressed but the main underlying
question is whether there is validity in taking such an approach.
Literature data even today have shown that preterms in the ICU are submitted to on average 10 painful
events without appropriate procedural analgesia.
To this effect a number of procedures have been evaluated as recently by Carbajal  using an enquiry et al
in many neonatal intensive care units and the use of analgesic and sedative drugs as published in the
Lancet 2015.
There is a significant variability in the use of different analgesics and the optimal analgesic so far is not
available for practice in daily NICU care.
Apart from a variety of non-pharmacological approaches, including swaddling and kangarooing,
pharmacological approaches can be divided in opioid and non-opioids while the latter can either be used
as long or short working analgesic drugs.
Morphine is a classic example of a drug that does not have an immediate effect and as such the trial
design is appropriate as the drug is given about 1 hour before the procedure.
This kind of approach has been used before for endotracheal intubation based on the concept that
intubation is a painful event which is mainly derived on experiences and questionnaires from adults.
Given the pharmacokinetic characteristics of morphine its mode of action and the slow time of onset it is
very questionable whether this approach of evaluating oral morphine for procedural pain in infants is of
value for our understanding and will change our attitude towards procedures like evaluation of retinopathy
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 value for our understanding and will change our attitude towards procedures like evaluation of retinopathy
of prematurity (ROP screening and heel lancing).
In fact a short working opioid related substance like fentanyl of one of the modern forms of fentanyl like-
substances needs a higher urgency of evaluation than going back to a classic drug like morphine of which
many clinicians will not be considering to give it 1 hour before a screening procedure.
Moreover there is a lack of data on the oral consumption and absorption of morphine which can lead to a
significant feeling of doubt of the relevance of this approach.
Although I appreciate the detailed way of the protocol description in which all the elements are nicely
documented and reported in a structured way the fundamental question whether this research is relevant
for this vulnerable group of patients is arguable.
 
My opinion is supported by 2 experts in evaluation of pain the newborn as well as a neonatologist –
clinical pharmacologist who I consulted within this process of writing this comment.
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
Author Response 18 Jan 2017
, University of Oxford, Oxford, UKRebeccah Slater
We would like to thank Dr Tibboel for reading and reviewing our Trial Protocol. In his report Dr
Tibboel suggests that although the study is well designed and described, he is not convinced that a
study of this type is warranted to test the analgesic efficacy of morphine for procedural pain in
prematurely born infants. We strongly disagree with this sentiment. If the results of this clinical trial
were to show that the administration of a single oral bolus dose of morphine prior to retinopathy of
prematurity screening (ROP) decreases noxious-evoked bran activity, reduces clinical pain scores,
and prevents physiological instability that is reported to occur in the 24-hour period post ROP
screening (characterised by an increase in the rates of apnoea, tachycardia, bradycardia and
oxygen desaturation), there would be a strong rationale for its use in clinical practice. This is
particularly important given that current treatment options for this procedure are not considered to
provide adequate analgesia. Furthermore, if the administration of oral morphine prior to painful
procedures is shown to be effective, it may also be useful for other painful procedures, and would
increase the treatment options available to infants. The fact that it would need to be given an hour
before a scheduled procedure should not negate its value. While morphine may be a ‘classic drug’
that is commonly administered to ventilated infants in intensive care, its primary use in this
population is as a sedative and there is still controversy regarding its analgesic efficacy (as
described in Dr Carbajal’s Referee Report). If the dose proposed here is effective this will also add
considerably to the limited dosing data available for oral morphine. Furthermore, inclusion of our
more recently developed measures of pain-related brain activity and the detailed physiological
monitoring will add greatly to our mechanistic understanding of how pharmacological analgesics
alter brain activity and physiological stability in prematurely-born infants. While we agree that it
would also be valuable to use a similar approach to test the analgesic efficacy of fentanyl (which
we are in the process of setting up), this does not negate the importance of testing the analgesic
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 we are in the process of setting up), this does not negate the importance of testing the analgesic
efficacy of morphine for procedural pain. 
 No competing interests were disclosed.Competing Interests:
 23 December 2016Reviewer Report
https://doi.org/10.21956/wellcomeopenres.10781.r18752
© 2016 Carbajal R. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution Licence
work is properly cited.
 Ricardo Carbajal
Center for Research on Epidemiology, Paris-Descartes University, Paris, France
This is the protocol of a blinded, placebo-controlled, parallel-group randomized, phase II, clinical trial that
will be undertaken to determine whether morphine sulphate administered orally prior to clinically-required
retinopathy of prematurity (ROP) screening and heel lancing provides effective analgesia. A total of 156
infants between 34 and 42 weeks’ corrected gestational age who require a clinical heel lance and ROP
screening on the same test occasion will be included in the trial. Infants will be randomised to receive
either a single dose of morphine sulphate (100 μg/kg) or placebo. Each infant will be monitored for 48
hours and safety data will be collected during the 24 hours following drug administration. The primary
outcome will be the Premature Infant Pain Profile–revised (PIPP-R) score during the 30-seconds period
after ROP screening. The co-primary outcome will be the magnitude of nociceptive-specific brain activity
evoked by a clinically-required heel lance.
This is a very relevant study because it aims at finding an effective analgesic strategy to reduce pain
during ROP screening since no analgesic approach so far published seems adequate. Furthermore, it will
contribute to obtain evidence of the analgesic efficacy of morphine in the neonate for procedural pain.
Conflicting evidence exists about the efficacy of continuous morphine to relieve pain from routine
procedures in ventilated preterm neonates. Two studies investigated their responses to tracheal
suctioning  ; in one of them, Anand  found a reduction in pain scores , whereas Simons  ,et al et al
judging from pain scores obtained with three validated scales, found no difference between morphine and
placebo groups . Pain measured by facial expression was diminished by morphine infusions during heel
stick in preterm and term neonates, but pain measures did not correlate with plasma morphine
concentrations . In another study, morphine given as a loading dose followed by continuous intravenous
infusions to less than 48-hours old ventilated neonates under 33 weeks gestation did not appear to
provide adequate analgesia for the acute pain caused by a heel stick . Thus, the use of two different
procedures as well as the use of two different ways of assessing pain in the current study will contribute to
a better understanding of the analgesic efficacy of morphine in neonates. Of note, at the time of the study
intervention, neonates will be at least two weeks old and between 34 and 42 corrected gestational age.
The close follow-up during 48 hours after the painful procedure is a major asset.
 
The protocol is very well written and interventions are very clearly and repeatedly explained. The
background section provides enough information to understand the importance of this study and the
rationale of using these two procedures. The trial design section shows in the text and in the
corresponding figure a clear outline of planned interventions. The safety monitoring section is complete
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 corresponding figure a clear outline of planned interventions. The safety monitoring section is complete
and gives clear indications of the assessments and reporting of adverse effects. The statistical analyses
are well presented and data management procedures seem very relevant.
 
Specific comments on sections
Background and rationale
Page 3. The explanation of the distress caused by ROP needs, in my opinion, to be clarified. When citing
Mitchell (Ref 14), it is said that the level of clinical distress caused by this procedure is exemplified in et al 
a recent study, which reports that in the 24-hour period following ROP screening 41% of infants have
apneic episodes compared to only 19% after the examination. In fact, this information does not seem to
correspond to what is mentioned in the article which indicates an apnea frequency of 12.8% before eye
examination, 23.07% within the first 24 hours after eye examination (p=0.13) and 30.7% from 25-48 hours
after eye examination (p=0.04).
Page 3. If the described plausibility that the administration of morphine prior to ROP screening may
provide effective pain relief and consequently reduce the resultant physiological instability caused by the
procedure is true, one interpretation would be that this procedure elicits a long lasting pain because of the
tissue damage or inflammation that may be created by the long lasting insertion of a speculum that pulls
apart the eyelids.
Page 4. While the use of nociceptive-specific brain activity may allow identifying patterns of nociceptive
brain activity, it should be kept in mind during the discussion and interpretation of results that pain is a
very complex phenomenon that could not be reduced to a very short lasting electrical activity. In a
previous paper of the authors, this brain activity that lasted less than 100 milliseconds was used as a
primary outcome to assess the analgesic efficacy of an oral sweet solution. In the current study, the
authors will use again an immediate nociceptive electrical signal during a heel lance but also measure
pain with a pain scale after the end of ROP screening. These two types of assessments seem
complementary.
Page 4. In the justification of the trial, the statement on the use of a dose of 200 µg/kg of oral morphine
does not correspond to the cited reference (Ref 37).
 
Trial design
Page 5. In box 1 and throughout the text, the description of the moment of the pain assessment for ROP
screening is a bit confusing. It is said that pain will be assessed with the PIPP-R score 30 seconds after
ROP screening. It would be more appropriate to say that pain will be assessed during the 30-seconds
period after ROP screening.
Page 5. Box 1, secondary outcome measures. The measurement of the incidence of apnea is only
relevant for non-intubated infants. This should be clarified because nowhere in the protocol it is indicated
that intubated infants will not be included. The use of an inotrope as a marker of hypotension requiring
intervention is in my opinion insufficient because in many occasions the first intervention for
morphine-induced hypotension will be volume replacement. Thus, this volume replacement should also
be monitored and reported.
Page 6. Inclusion-exclusion criteria. It should be clarified that intubated and non-intubated infants will be
included.
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 1.  
2.  
3.  
4.  
5.  
6.  
included.
Page 7. Figure 2. In the exclusion criteria box, correct “…born to mothers who regularly used opiates…”
Page 11. Reflex withdrawal. Reference 38 does not correspond to this statement; it should be reference
numbered 37.
Page 11. Safety of administration of oral morphine. As indicated above the incidence of apnea is only
relevant to non-intubated infants.
Page 12. Concomitant medications. The assertion “At present infants do not receive any pain medication
prior to heel lancing so it is acceptable that the control group receive a placebo (inactive solution) with no
medicinal effects.” Is not true everywhere. Indeed, the opposite is becoming true. Guidelines for
managing painful procedures in different countries indicate the use of sucrose for heel lance. For instance
a joint position statement from the Canadian Paediatric Society and the American Academy of Pediatrics
recommend that a combination of oral sucrose/glucose and other nonpharmacological pain reduction
methods (nonnutritive sucking, kangaroo care, facilitated tuck, swaddling and developmental care) should
be used for minor, routine procedures ; this recommendation was ratified in 2016 . In the UK, The Royal
College of Anaesthetists recommends, in its Core standards for pain management services in the UK, the
use of sucrose for painful procedures in infants.
 
In conclusion, this is a very interesting and relevant protocol that addresses an important issue in neonatal
pain management. It should contribute to the improvement of analgesic practices in this vulnerable
population.
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This is a very well described study design to evaluate the impact of morphine administration on the pain
expression during both ROP screening and heel lancing. Also the additional procedures (how the
screening and lancing will be performed, additional interventions like swaddling, dilatation eye drops and
local anaesthetics) are well described. This study design has the potential to provide an answer on the
potential relevance of morphine for both procedural interventions after these ‘conventional interventions’
but alternative approaches (eg. venepuncture instead of heel lancing, or using less painful procedures of
ROP screening or not considered).
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